Plain-English translation of NCT07677059 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a follow-up study for people with asthma who participated in an earlier trial of . Researchers want to understand how safe and effective this medication is when taken for a longer period of time, and how it continues to behave in your body.
Early testing showed promise, but doctors need to know whether this medication stays safe and works well over months or years of regular use — not just over a few weeks.
You likely qualify if…
You likely don't qualify if…
You will continue taking the same medication you received in the earlier trial and attend regular study visits to check on your asthma control and any side effects. You'll complete lab tests and use an electronic diary to record how you're doing. The study is designed to follow you long-term to make sure the medication remains safe and effective.
AI-generated summary from trial data · Jul 13, 2026 · Not medical advice
United States
Sponsor
Kymera Therapeutics, Inc.
Enrollment target
~264 participants
Started
July 2026
Primary completion
December 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Kymera Medical Director
Kymera Therapeutics, Inc.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.